Selected article for: "agarose gel analysis and gel analysis"
Author: Adriaan H. de Wilde; A. Linda Boomaars-van der Zanden; Anja W. M. de Jong; Montserrat Barcéna; Eric J. Snijder; Clara C. Posthuma
Title: Inhibition of arterivirus RNA synthesis by cyclophilin inhibitors is counteracted by mutations in replicase transmembrane subunits
  • Document date: 2019_3_24
    • ID: l5n30kbm_22
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/587261 doi: bioRxiv preprint presence of 8 µM of CsA (which was added 1 h prior to the pulse labeling), rEAV wt RNA synthesis 362 was completely blocked, while rEAV QYA RNA synthesis was hardly affected, as evident from both the 363 overall quantification of 3 H-labeled RNA and the RNA analysis using agarose gel electrophoresis ( .....
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/587261 doi: bioRxiv preprint presence of 8 µM of CsA (which was added 1 h prior to the pulse labeling), rEAV wt RNA synthesis 362 was completely blocked, while rEAV QYA RNA synthesis was hardly affected, as evident from both the 363 overall quantification of 3 H-labeled RNA and the RNA analysis using agarose gel electrophoresis ( The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/587261 doi: bioRxiv preprint Alisporivir (ALV) (de Wilde et al., 2017), a drug that was explored as a host-directed antiviral 389 treatment option for chronic HCV infection (Naoumov, 2014) . ALV lacks the immunosuppressive 390 properties of CsA, while retaining a high affinity for cyclophilins. We now established that ALV is 391 able to block also the replication of wtEAV with an EC50 value of 4.5 ± 0.2 µM, an efficiency that is 392 comparable to that observed for CsA (Table 3) . 393

    Search related documents:
    Co phrase search for related documents
    • agarose gel electrophoresis and high affinity: 1
    • agarose gel electrophoresis and QYA RNA synthesis: 1
    • agarose gel electrophoresis and rEAV QYA RNA synthesis: 1
    • agarose gel electrophoresis and RNA analysis: 1, 2, 3, 4, 5
    • agarose gel electrophoresis and wt RNA synthesis: 1
    • chronic HCV infection and HCV infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
    • chronic HCV infection and treatment option: 1
    • gel electrophoresis and high affinity: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • gel electrophoresis and QYA RNA synthesis: 1
    • gel electrophoresis and rEAV QYA RNA synthesis: 1
    • gel electrophoresis and RNA analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • gel electrophoresis and wt RNA synthesis: 1
    • HCV infection and high affinity: 1
    • HCV infection and host direct: 1
    • HCV infection and RNA analysis: 1, 2
    • HCV infection and treatment option: 1
    • high affinity and RNA analysis: 1, 2, 3, 4
    • high affinity and treatment option: 1, 2, 3, 4
    • pulse labeling and RNA analysis: 1